Nektar Therapeutics (NKTR) Fall Likely To Hurt Mannkind Corp (MNKD)

Nektar Therapeutics (Nasdaq: NKTR) ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. An increase in the number of new cases of lung cancer was observed in inhaled insulin patients as compared to the control group. All new incidences of lung cancer were in patients that are former smokers.

This negative news from Nektar will likely hurt MannKind (Nasdaq: MNKD), who was also working on a product related to 'inhaled insulin'.

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!

You May Also Be Interested In

• Softbank Group Plans ¥1 Trillion Retail Bond Sale - Bloomberg
• NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
• Nscale targets up to $3B in US IPO as soon as September - Bloomberg